Notes - Segment Information, Etc.

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. - Filing #7598175

Concept 2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
Notes - Segment information, etc.
Segment information
Disclosure of sales, profit (loss), asset, liability, and other items for each reportable segment
Sales
Revenues from external customers
17,484,011,000 JPY
264,470,000 JPY
528,035,000 JPY
12,062,000 JPY
17,748,482,000 JPY
JPY
16,943,913,000 JPY
17,748,482,000 JPY
14,960,464,000 JPY
150,083,000 JPY
12,242,000 JPY
512,939,000 JPY
JPY
15,110,548,000 JPY
15,110,548,000 JPY
14,435,282,000 JPY
Transactions with other segments
140,201,000 JPY
704,498,000 JPY
35,462,000 JPY
800,000 JPY
844,700,000 JPY
-844,700,000 JPY
103,938,000 JPY
JPY
112,807,000 JPY
353,787,000 JPY
JPY
39,239,000 JPY
-466,595,000 JPY
JPY
466,595,000 JPY
73,567,000 JPY
Other items
Depreciation
1,014,589,000 JPY
162,843,000 JPY
94,963,000 JPY
3,421,000 JPY
1,177,432,000 JPY
JPY
916,203,000 JPY
1,177,432,000 JPY
1,022,036,000 JPY
165,647,000 JPY
472,000 JPY
91,251,000 JPY
JPY
1,187,684,000 JPY
1,187,684,000 JPY
930,313,000 JPY
Equity in earnings (losses) of affiliates
1,439,573,000 JPY
-255,000 JPY
JPY
JPY
1,439,317,000 JPY
JPY
1,439,573,000 JPY
1,439,317,000 JPY
846,498,000 JPY
-215,000 JPY
JPY
JPY
JPY
846,283,000 JPY
846,283,000 JPY
846,498,000 JPY
Increase in property, plant and equipment and intangible assets
1,274,913,000 JPY
464,648,000 JPY
186,208,000 JPY
18,503,000 JPY
1,739,562,000 JPY
-35,772,000 JPY
1,070,200,000 JPY
1,703,789,000 JPY
864,505,000 JPY
167,466,000 JPY
28,786,000 JPY
330,925,000 JPY
-6,741,000 JPY
1,025,230,000 JPY
1,031,971,000 JPY
504,794,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.